Atrial fibrillation (AF) is the most common cardiac arrhythmia and the occurrence of AF increases with age. The prevalence of AF rises from 0.5% in people in their 50s to 5% in people over the age of 65 years. This rises to nearly 10% in the octogenarian population. 1 AF is a major cause of morbidity and mortality, increasing the risk of death, congestive heart failure (CHF) and embolic phenomena, including stroke. 1 It is believed that AF is a lifetime risk in the ageing population 2 and it is emerging as a major public health concern. 3 The management of AF includes surgery, ablation 4, 5 and pharmacological therapies. 6 However, only some cases are amenable to surgical or ablative therapies, and most of them require antiarrhythmic drug treatment. 6 Over the years, delayed rectifier K + currents (I K ), especially the rapidly-activating I K (I Kr , encoded by hERG, ether-a-go-go gene), have been important targets for antiarrhythmic drugs. Blockade of these ion channels (class III antiarrhythmic drugs) leads to a prolongation of atrial and ventricular action potential duration (APD) and the refractory period, which is the desired antiarrhythmic effect. 7, 8 However, prolongation of ventricular repolarisation causes a prolongation of the QT interval and an increased propensity for life-threatening ventricular arrhythmias. 9 Therefore, there is a clear need to develop new drugs that may act mainly on electrical activity in the atrium of the human heart to prevent or treat AF.
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Ion Channel Currents in the Atrium and

Ventricle of the Human Heart
It is well-known that human cardiac APD and the refractory period generally depend on the balance of inward and outward currents in atrial and ventricular myocytes (see Figure 1) . Inward currents include the Na + current (I Na ) and L-type Ca 2+ current (I Ca.L ), and outward currents include the transient outward K + current (I to ), I Kr and slowly-activating delayed rectifier K + current (I Ks ) and inward rectifier K + current (I K1 ). In general, I Na channel activation depolarises cell membrane and initiates action potential (phase 0), then I to activation forms a fast repolarisation (phase 1).
Activation of I Ca.L maintains the plateau of the action potential (phase 2); I Kr and I Ks gradually activate and induce slow repolarisation during phase 2. Finally, activation of I K1 channels induces final repolarisation (phase 3) and maintains resting membrane potential (phase 4). The electrogenic Na + -Ca 2+ exchanger mainly carries an inward current and also plays a role in maintaining the plateau of cardiac action potential.
It is interesting that ultrarapidly activating delayed rectifier K + channel (encoded by Kv1.5 gene) current (I Kur ) was found to be functionally present in the atrium 10 but not in the ventricle of the human heart. 11 It is important for human atrial repolarisation. In addition, acetylcholine-activated K + channels (I KACh , mediated by muscarinic receptors) are dominantly distributed in the atrium of the human heart and also contribute to human atrial repolarisation (see Figure 1 ). It has recently been reported that I K.ACh and muscarinic receptor expression are upregulated in AF patients 12 and in AF induced in experimental dogs with heart failure. 13 Therefore, blockage of I KACh could terminate AF induced by the increased vagal nerve tone. It is believed that blockade of atrial K + channels (I Kur and/or I KACh ) could provide an approach for the control of atrial arrhythmias without adverse ventricular effects. Therefore, the compounds targeted to I Kur and/or I KACh would be promising agents for developing selective anti-AF drugs.
Atrial-specific Ion Channel Blockers
The pharmaceutical industry has recently made great progress in the development of new antiarrhythmic drugs to treat AF. The design of selective anti-AF drugs pays more attention to compounds that block the atrial-specific I Kur and/or I KACh . 14, 15 It is believed that one of the feared side effects of class III drugs -torsades de pointes arrhythmias -can be overcome by developing a drug that lengthens only the duration of the atrial action potential without increasing the QT interval. Moreover, the dose of the drug needed for effectiveness will be less limited. Several compounds that block hKv1.5 channels and/or native I Kur 19 In addition, AVE0118 was found to significantly prolong the atrial refractory period and completely prevent vulnerability to AF induced by extra stimuli in pigs. 20 Importantly, this compound showed excellent anti-AF action in a chronic AF goat model. 21 A phase II clinical trial of AVE0118 is under way. NIP-141 and NIP-142 are novel benzopyran derivatives developed by Nissan Chemicals. They inhibit human atrial I Kur and I to . 22, 23 It was experimentally demonstrated that NIP-142 had an inhibitory effect on I KACh in guinea pig atrium 24 and suppressed AF and atrial flutter in a dog model. 25 
Multiple Channel Blockers
The Na + -channel blockade is believed to be highly effective in terminating AF by causing primary re-entry waves. 33 Therefore, the I Na blocking effect is likely beneficial for a compound that selectively blocks atrial K + channels.
RSD1235 (vernakalant) is a new antiarrhythmic agent developed by
Cardiome. Vernakalant showed multiple ion channel-blocking effects, including properties of frequency-dependent Na + -channel blockade and atrial-preferential potassium-channel (I Kur and I to ) blockade. 34 This compound has been evaluated as an intravenous agent for acute conversion of AF. At a dose of 3mg/kg followed by another 2mg/kg after 15 minutes, vernakalant resulted in 52% conversion of new-onset AF versus 4% with placebo. There was no evidence of QT prolongation or proarrhythmia. 35 AZD7009 is a new antiarrhythmic agent developed by AstraZeneca. This compound showed both Na + and K + (hERG and I Ks ) current blocking properties. 36 In a canine model, AZD7009 terminated AF and flutter and prevented re-induction. Atrial refractoriness was prolonged to a greater degree than ventricular refractoriness (33 versus 17%) and QT prolongation was modest. 37 A recent phase II dose-dependent study demonstrated that AZD7009 resulted in acute conversion in patients with recent onset of AF or flutter. QT prolongation was also observed. 38 Therefore, caution is advised when using this compound.
Perspective
A number of promising atrial-specific drugs have been developed from chemically synthesised compounds or natural compounds for anti-AF.
Hopefully, it will mark the beginning of a clinically exciting time in anti-AF testing. Despite the advances of numerous alternatives, pharmacological treatment of AF will prevail in the near future. ■ 
